CHRYSTAL SHIRLEY: Open Payments
NPI 1639759764 · LEESBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,113 in 51 payments from 12 companies in 2025. Trend: 2023 $1,580 · 2024 $1,179 · 2025 $1,113
Food & beverage: $1,113
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $207 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $194 |
| Neurocrine BioSciences, Inc. | 5 | $147 |
| Alkermes, Inc. | 7 | $144 |
| Janssen Pharmaceuticals, Inc | 4 | $93 |
| ABBVIE INC. | 4 | $91 |
| E.R. Squibb & Sons, L.L.C. | 3 | $62 |
| Luye Pharma (USA) Ltd. | 2 | $46 |
| ACADIA Pharmaceuticals Inc | 1 | $45 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $31 |
Products named: CAPLYTA, AUSTEDO XR, INGREZZA, INVEGA SUSTENNA, VRAYLAR, ARISTADA, LYBALVI, COBENFY.
Industry payments across FL — which companies pay providers there.
